BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 32666469)

  • 1. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
    Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
    Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.
    Zhang Q; Wei A; Ma HH; Zhang L; Lian HY; Wang D; Zhao YZ; Cui L; Li WJ; Yang Y; Wang TY; Li ZG; Zhang R
    Haematologica; 2021 Jul; 106(7):1892-1901. PubMed ID: 32732367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
    J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
    Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
    Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.
    Meng G; Wang J; Wang X; Wang Y; Wang Z
    Ann Hematol; 2020 Feb; 99(2):343-349. PubMed ID: 31879790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.
    Zhang Q; Zhao YZ; Ma HH; Wang D; Cui L; Li WJ; Wei A; Wang CJ; Wang TY; Li ZG; Zhang R
    Blood; 2022 Jun; 139(24):3493-3504. PubMed ID: 35344583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
    Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
    [No Abstract]   [Full Text] [Related]  

  • 8. HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center.
    Song Y; Wang J; Wang Y; Wang Z
    Stem Cell Res Ther; 2020 Jul; 11(1):265. PubMed ID: 32611452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.
    Xu Y; Li W; Gan J; He X; Huang X
    Ann Hematol; 2023 Dec; 102(12):3325-3333. PubMed ID: 37787838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.
    Song Y; Li X; He X; Zhou F; Du F; Wang Z; Chen S; Wu D
    Front Immunol; 2023; 14():1211655. PubMed ID: 37457729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
    Wang J; Zhang R; Wu X; Li F; Yang H; Liu L; Guo H; Zhang X; Mai H; Li H; Wang Z
    Br J Haematol; 2021 May; 193(4):761-768. PubMed ID: 33559893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH.
    Shamriz O; Kumar D; Shim J; Briones M; Quarmyne MO; Chonat S; Lucas L; Edington H; White MH; Mahajan A; Park S; Chandrakasan S
    J Clin Immunol; 2021 Oct; 41(7):1582-1596. PubMed ID: 34173902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
    Yan WL; Yang SL; Zhao FY; Xu XJ
    J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis.
    Wang Y; Huang W; Hu L; Cen X; Li L; Wang J; Shen J; Wei N; Wang Z
    Blood; 2015 Nov; 126(19):2186-92. PubMed ID: 26289641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
    Jianguo L; Zhixuan Z; Rong L; Xiaodong S
    Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoma-based therapy for refractory or relapsed Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in children.
    Cheng CN; Chu WY; Chang KC; Chen JS
    J Formos Med Assoc; 2022 Nov; 121(11):2351-2355. PubMed ID: 35123848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical analysis and follow-up study of Epstein-Barr virus associated-hemophagocytic lymphohistiocytosis in childhood].
    Lu G; Xie ZD; Shen KL; Wu RH; Jin YK; Yang S; Liu CY
    Zhonghua Er Ke Za Zhi; 2010 Feb; 48(2):121-6. PubMed ID: 20426937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.
    Liu X; Zhu X; Zhou X; Xie Y; Xiang D; Wan Z; Huang Y; Zhu B
    Front Immunol; 2022; 13():1012643. PubMed ID: 36263041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
    Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
    Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [L-DEP regimen salvage therapy for refractory primary hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection in 4 children].
    Zhao YZ; Ma HH; Lian HY; Wang D; Wang TY; Zhang R
    Zhonghua Er Ke Za Zhi; 2024 May; 62(5):467-472. PubMed ID: 38623016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.